City Therapeutics' (NASDAQ:CTY - Get Free Report) quiet period will expire on Wednesday, November 25th. City Therapeutics had issued 11,111,111 shares in its IPO on October 16th. The total size of the offering was $199,999,998 based on an initial share price of $18.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Wall Street Zen upgraded shares of City Therapeutics to a "hold" rating in a research note on Saturday, October 24th. Jefferies Financial Group assumed coverage on shares of City Therapeutics in a report on Monday. They issued a "strong-buy" rating on the stock. Stifel Nicolaus started coverage on shares of City Therapeutics in a research report on Tuesday, November 10th. They set a "buy" rating and a $34.00 price objective for the company. Oppenheimer began coverage on City Therapeutics in a report on Tuesday, November 10th. They set an "outperform" rating and a $46.00 price objective for the company. Finally, Zacks Research assumed coverage on City Therapeutics in a report on Wednesday, November 11th. They set a "hold" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $37.33.
View Our Latest Stock Report on CTY
City Therapeutics Stock Up 3.1%
Shares of City Therapeutics stock opened at $17.50 on Wednesday. City Therapeutics has a 52-week low of $15.81 and a 52-week high of $23.88.
Insider Transactions at City Therapeutics
In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the business's stock in a transaction on Monday, October 19th. The stock was purchased at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the insider directly owned 13,692,507 shares of the company's stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Nelsen acquired 170,000 shares of the business's stock in a transaction on Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.
About City Therapeutics
(
Get Free Report)
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company's activities center on building a therapeutic pipeline rather than marketing established products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider City Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and City Therapeutics wasn't on the list.
While City Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.